ArticleHypertension (Dallas, Tex. : 1979)2023
Increased Placental sFLT1 (Soluble fms-Like Tyrosine Kinase Receptor-1) Drives the Antiangiogenic Profile of Maternal Serum Preceding Preeclampsia but Not Fetal Growth Restriction.
Article in Hypertension (Dallas, Tex. : 1979), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Isthmin-2 is a first-trimester predictor of preeclampsia and fetal growth restriction.Nature medicine · 2026Article
- Mechanisms of the Oral-Gut Microbiota Axis in Adverse Pregnancy Outcomes.Microorganisms · 2026Review
- Concordant and Discordant Transcriptomic Signatures of Twin Placentas in the Setting of Preeclampsia.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Circulating levels of sFlt-1 and AT1-AA in women with prior preeclampsia: a 10-year postpartum cross-sectional analysis (PERLA-Brazil study).Scientific reports · 2026Article
- Placental dysfunction drives fetal growth restriction: mechanisms and translational perspectives.Frontiers in molecular biosciences · 2026Review
- Microchimerism and pregnancy complications with placental dysfunction.Seminars in immunopathology · 2025Review
- Soluble Fms-like tyrosine kinase-1 polymorphisms associated with severe-spectrum hypertensive disorders of pregnancy.Archives of gynecology and obstetrics · 2025Article
- Maternal Microvascular Dysfunction During and After Preeclamptic Pregnancy.Comprehensive Physiology · 2024Review
- Placental Origins of Preeclampsia: Insights from Multi-Omic Studies.International journal of molecular sciences · 2024Review
- Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach.Bioactive materials · 2024Article
- The Current Role of the sFlt-1/PlGF Ratio and the Uterine-Umbilical-Cerebral Doppler Ultrasound in Predicting and Monitoring Hypertensive Disorders of Pregnancy: An Update with a Review of the Literature.Children (Basel, Switzerland) · 2023Review
- Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023Review
- MIF Increases sFLT1 Expression in Early Uncomplicated Pregnancy and Preeclampsia.International journal of molecular sciences · 2023Article
- Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction.Clinical science (London, England : 1979) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundPreeclampsia and fetal growth restriction (FGR) are both associated with an increased ratio of sFLT1 (soluble fms-like tyrosine kinase-1) to PlGF (placenta growth factor) in maternal serum. In preeclampsia, it is assumed that increased placental release of sFLT1 results in PlGF being bound and inactivated. However, direct evidence for this model is incomplete, and it is unclear whether the same applies in FGR.
methodsWe conducted a prospective cohort study where we followed 4212 women having first pregnancies from their dating ultrasound, obtained blood samples serially through the pregnancy, and performed systematic sampling of the placenta after delivery. The aim of the present study was to determine the relationship between protein levels of sFLT1 and PlGF in maternal serum measured at ≈36 weeks and placental tissue lysates obtained after term delivery in 82 women with preeclampsia, 50 women with FGR, and 132 controls.
resultsThe sFLT1:PlGF ratio was increased in both preeclampsia and FGR in both the placenta and maternal serum. However, in preeclampsia, the maternal serum ratio of sFLT1:PlGF was strongly associated with placental sFLT1 level (r=0.45;
conclusionsWe conclude that the elevated sFLT1:PlGF ratio is primarily driven by increased placental sFLT1 in preeclampsia, whereas in FGR, it is primarily driven by decreased placental PlGF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.